SKLB1002 is a potent small-molecule inhibitor primarily investigated for its antitumor activity. It functions by selectively targeting and inhibiting specific kinase enzymes involved in cancer cell proliferation and survival pathways. Due to its ability to block aberrant signaling in tumor cells, SKLB1002 has shown promise in preclinical studies for treating various solid tumors. It demonstrates strong inhibitory effects on cancer cell growth, induces apoptosis, and suppresses metastasis in experimental models. Its application is mainly focused on oncology research, particularly in the development of targeted therapies for cancers with dysregulated kinase activity. Ongoing studies aim to evaluate its efficacy, pharmacokinetics, and safety profile for potential future use in clinical settings.